<SEC-DOCUMENT>0001171843-15-004409.txt : 20150806
<SEC-HEADER>0001171843-15-004409.hdr.sgml : 20150806
<ACCEPTANCE-DATETIME>20150806085336
ACCESSION NUMBER:		0001171843-15-004409
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150805
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150806
DATE AS OF CHANGE:		20150806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		151031293

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 8-K FILING DOCUMENT
<TEXT>
<!DOCTYPE html
	PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"
	"http://www.w3.org/TR/html4/loose.dtd">

<html lang="en-US">

	<head>
		<title>Form 8-K Filing</title>
	</head>

	<body>
		<p align="center"><font size="5"><b>UNITED STATES<br>
					SECURITIES AND EXCHANGE COMMISSION<br>
				</b></font></p>
		<p align="center"><font size="3"><b>Washington, D.C. 20549</b><br>
			</font></p>
		<hr noshade="1" width="150" align="center">
		<p align="center"><font size="5"><b>FORM 8-K</b><br>
			</font></p>
		<hr noshade="1" width="150" align="center">
		<p align="center"><font size="3"><b>CURRENT REPORT</b><br>
			</font></p>
		<p align="center"><font size="3"><b>Pursuant to Section&nbsp;13 or 15(d) of<br>
					The Securities Exchange Act of 1934</b><br>
			</font></p>
		<p align="center"><font size="3">Date of Report (Date of earliest event reported): <b>August 5, 2015</b>&nbsp; <br>
			</font></p>
		<hr noshade="1" width="150" align="center">
		<p align="center"><font size="5"><b>BioCryst Pharmaceuticals, Inc.</b></font><br>
			<font size="2">(Exact name of registrant as specified in its charter) </font></p>
		<!-- Registrant's State of Inc, File and IRS Number -->
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="33%" align="center"><font size="2"><b>Delaware</b></font></td>
				<td width="34%" align="center"><font size="2"><b>000-23186</b></font></td>
				<td width="33%" align="center"><font size="2"><b>62-1413174</b></font></td>
			</tr>
			<tr valign="top">
				<td width="33%" align="center"><font size="2">(State or other jurisdiction<br>
						of incorporation) </font></td>
				<td width="34%" align="center"><font size="2">(Commission File Number) </font></td>
				<td width="33%" align="center"><font size="2">(IRS Employer Identification No.) </font></td>
			</tr>
		</table>
		<!-- Registrant's Postal Addess and Zip Code --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="50%" align="center"><font size="2"><b>4505 Emperor Blvd., Suite 200<br>
Durham, North Carolina </b></font></td>
				<td width="50%" align="center" valign="bottom"><font size="2"><b>27703</b></font></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"><font size="2">(Address of principal executive offices) </font></td>
				<td width="50%" align="center"><font size="2">(Zip Code) </font></td>
			</tr>
		</table>
		<p align="center"><font size="2">Registrant's telephone number, including area code: &nbsp; <b>(919) 859-1302</b></font></p>
		<p align="center"><font size="2">
			________________________________________________________________________________<br>
			(Former name or former address, if changed since last report)</font></p>
		<!-- Simultaneous filing obligation checkboxes -->
		<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></td>
			</tr>
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></td>
			</tr>
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></td>
			</tr>
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></td>
			</tr>
		</table>
		<br>
		<hr noshade="1">
		<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"></div>

		<p><font size="3"><b><p><font size="3"><b>Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></font></p></b></font></p>
		<p><font size="2"><P >
	On August 5, 2015, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the &#034;Company&#034;) elected Robert A. Ingram to the Company&#039;s Board of Directors.  The Company issued a news release reporting this matter on August 6, 2015, and a copy of the news release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.</P>
<P >
	The Company&#039;s Board of Directors also appointed Mr. Ingram to serve on each of its Compensation Committee and its Corporate Governance and Nominating Committee effective upon his election to the Board of Directors.</P>
<P >
	Pursuant to the Company&#039;s Stock Incentive Plan, Mr. Ingram will receive an automatic grant of 18,750 stock options upon joining the Board of Directors, and will be entitled to a grant of 15,000 stock options after each annual stockholders&#039; meeting.  Mr. Ingram will receive compensation consistent with the Company&#039;s director compensation policy as described in the Company&#039;s proxy statement for its 2015 annual meeting of stockholders. </P>
</font></p>

		<p><font size="3"><b><p><font size="3"><b>Item 9.01. Financial Statements and Exhibits.</b></font></p></b></font></p>
		<p><font size="2"><P  align="center">
	<table border="0" cellpadding="0" cellspacing="0" width="100%">

			<tr>
				<td colspan="3" nowrap="nowrap" valign="bottom">
					<P  align="left">
						<u><font style ="font-size:12px;"><b>Exhibit No.</b></font></u></P>
				</td>
				<td valign="bottom">
					<P  align="left">
						<font style ="font-size:12px;"><b> </b></font></P>
				</td>
				<td nowrap="nowrap" valign="bottom">
					<P  align="left">
						<u><font style ="font-size:12px;"><b>Description</b></font></u></P>
				</td>
			</tr>
			<tr>
				<td nowrap="nowrap" valign="top">
					<P  align="left">
						<font style ="font-size:12px;"><br />
						</font></P>
				</td>
				<td valign="top">
					<P  align="left">
						<font style ="font-size:12px;">99.1</font></P>
				</td>
				<td nowrap="nowrap" valign="top">
					<P  align="left">
						<font style ="font-size:12px;"><br />
						</font></P>
				</td>
				<td valign="top">
					<P  align="left">
						<font style ="font-size:12px;"><br />
						</font></P>
				</td>
				<td valign="top">
					<P  align="left">
						<font style ="font-size:12px;">Press Release dated August 6, 2015 entitled &#034;Robert Ingram Appointed to BioCryst&#039;s Board Of Directors&#034;</font></P>
				</td>
			</tr>

	</table>
</P>
</font></p>
		<hr noshade="1">
		<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"></div>
		<!-- Registrant's Signature -->
		<p align="center"><font size="3"><b>SIGNATURE</b> </font></p>
		<p><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%">&nbsp;</td>
				<td width="5%">&nbsp;</td>
				<td width="47%" align="center"><font size="2"><b>BioCryst Pharmaceuticals, Inc.</b>
					<hr noshade>
					(Registrant)</font><br>
					<br>
				</td>
			</tr>
			<tr valign="top">
				<td width="47%" align="center"><font size="2"><b>August 6, 2015</b>
					<hr noshade>
					(Date)</font></td>
				<td width="5%">&nbsp;</td>
				<td width="47%" align="center"><font size="2"><b>/s/ &nbsp; ALANE BARNES</b></font>
					<hr noshade>
					<font size="2">Alane Barnes</font><br>
					<font size="2"><i>Vice President, General Counsel,<br> and Corporate Secretary</i></font></td>
			</tr>
		</table>
		<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"></div>
		<hr />
<P  align="center">
	<font style ="font-size:12px;"><b>EXHIBIT INDEX</b></font></P>
<P  align="left">
	<font style ="font-size:12px;"><b> </b></font></P>
<P  align="center">
	<table border="0" cellpadding="0" cellspacing="0" width="100%">

			<tr>
				<td colspan="3" nowrap="nowrap" valign="bottom">
					<P  align="left">
						<u><font style ="font-size:12px;"><b>Exhibit No.</b></font></u></P>
				</td>
				<td valign="bottom">
					<P  align="left">
						<font style ="font-size:12px;"><b> </b></font></P>
				</td>
				<td nowrap="nowrap" valign="bottom">
					<P  align="left">
						<u><font style ="font-size:12px;"><b>Description</b></font></u></P>
				</td>
			</tr>
			<tr>
				<td nowrap="nowrap" valign="top">
					<P  align="left">
						<font style ="font-size:12px;"><br />
						</font></P>
				</td>
				<td valign="top">
					<P  align="left">
						<font style ="font-size:12px;">99.1</font></P>
				</td>
				<td nowrap="nowrap" valign="top">
					<P  align="left">
						<font style ="font-size:12px;"><br />
						</font></P>
				</td>
				<td valign="top">
					<P  align="left">
						<font style ="font-size:12px;"><br />
						</font></P>
				</td>
				<td valign="top">
					<P  align="left">
						<font style ="font-size:12px;">Press Release dated August 6, 2015 entitled &#034;Robert Ingram Appointed to BioCryst&#039;s Board Of Directors&#034;</font></P>
				</td>
			</tr>

	</table>
</P>

	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>Robert Ingram Appointed to BioCryst's Board of Directors</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">Robert Ingram Appointed to BioCryst's Board of Directors</h3><p>RESEARCH TRIANGLE PARK, N.C., Aug. 6, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Robert A. Ingram was elected to the Company's Board of Directors.</p><p>
	"The Board of Directors and Leadership Team of BioCryst are very pleased to have Bob Ingram join the Company's Board," said George B. Abercrombie, Chairman of the Board of BioCryst. "Bob brings a wealth of pharmaceutical leadership, and public company board experience to the BioCryst Board. We look forward to his insights and contributions as we work with the BioCryst team to build the leading oral drug rare disease company."</p><p>
	Bob Ingram joined Hatteras Venture Partners as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline (GSK) and served as Vice Chairman Pharmaceuticals of GSK until January 1, 2010.</p><p>
	Bob serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc., and is Chairman of Viamet. He is also a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. Bob graduated from Eastern Illinois University with a B.S. degree in Business Administration.</p><p>
	In addition to his professional responsibilities, Bob formed and chaired the CEO Roundtable on Cancer at the request of former President George H.W. Bush, and he is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.</p><p>
	Bob is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of the Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy &amp; Economics, University of Southern California.</p><p>
	"Over the last few years, the Leadership Team and Board has made significant progress toward building BioCryst to be the rare disease, oral drug company, based on its successful structure based drug design platform," said Robert A. Ingram. "I look forward to working with the BioCryst organization and Board of Directors to advance the company toward further success in drug development and commercialization for the benefit of patients."</p><p>
	<strong>About BioCryst Pharmaceuticals </strong></p><p>
	BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.&#160; BioCryst's ongoing development programs include oral plasma kallikrein inhibitors for hereditary angioedema, BCX4161, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.&#160;</p><p>
	This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.</p><p>
	BCRXW</p><pre>CONTACT: Robert Bennett,
         BioCryst Pharmaceuticals,
         +1-919-859-7910
         (investors &amp; media)</pre></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
